Melanoma Clinical Trials in Dallas

Showing 181-200 of 268 trials

WITHDRAWNPhase 2< 1 mile

SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients

NCT03126461

A one-arm, single center phase 2 trial of SAbR plus ipilimumab plus nivolumab in advanced metastatic melanoma patients

MelanomaMetastatic Melanoma

University of Texas Southwestern Medical CenterStarted Mar 2018

Dallas, Texas, United States

COMPLETEDPhase 3< 1 mile

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

NCT01989572

This randomized phase III trial studies sargramostim or vaccine therapy alone to see how well they work compared to sargramostim and vaccine therapy together in preventing disease recurrence in patients with melanoma that has been removed by surgery. Sargramostim may stimulate the immune system in different ways and stop tumor cells from growing. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. It is not yet known whether yeast derived sargramostim and vaccine therapy are more effective alone or together in preventing recurrence of melanoma.

Iris MelanomaMedium/Large Size Posterior Uveal MelanomaMucosal Melanoma+17 more

National Cancer Institute (NCI)815 participantsStarted Feb 2000

Birmingham, Alabama, United States • Mobile, Alabama, United States • Scottsdale, Arizona, United States +145 more locations

SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

Melanoma Trials in Other Cities

A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec

CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)

A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma

X4P-001 and Pembrolizumab in Patients With Advanced Melanoma

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery

A Study of Tasisulam in Treating Participants With Malignant Melanoma

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Other Conditions in Dallas